Dyadic Announces Launch of Fibrezyme® G4

Fibrezyme^® G4 has shown to reduce energy requirements and increase production rates for pulp and paper manufacturers. In addition, Fibrezyme^® G4 enhances and restores fiber strength and increases inter-fiber bonding in paper-making applications. In the textile industry, Fibrezyme^® G4 will be used to soften denim and create a stonewashed look for blue jeans. Fibrezyme^® G4 operates under wide pH and temperature ranges allowing for improved integration into a variety of pulp and paper and textile manufacturing processes.

Danai Brooks, Dyadic’s Chief Operating Officer stated, “Fibrezyme^® G4 is a new addition to our product portfolio and provides further evidence of the capabilities of Dyadic’s C1 platform technology. We expect two key markets to be China and South Asia, which are growing and open to new entrants like Dyadic. Interest in pulp and paper enzymes in South Asia continues to grow in both commercial applications and innovation. South Asia is also one of the world’s largest textile enzyme markets. Over the past year, China has become an important part of our pulp and paper strategy as we continue to strengthen our commercial relationships in that country. In addition, government policy is increasingly focused on the environmental impact of mills, which is expected to drive up demand for enzymes like Fibrezyme^® G4.”

Dyadic’s Vice President of Operations, Rich Jundzil, added “Fibrezyme® G4 represents the next generation of C1-based products produced using the White Strain, the latest addition to Dyadic’s patented and proprietary C1 platform. In our manufacturing process, the White Strain produces purer proteins, which allows us to make more of the protein of interest with a reduction in unwanted side activities. This technology allows for more efficient industrial scale production of highly targeted enzymes that are specifically designed to meet the needs of our customers. The White Strain continues to broaden the reach of the C1 platform into new applications for the pharmaceutical, food, animal feed, brewing, baking, and other industrial markets.” Fibrezyme^® G4 became available to customers beginning in March of 2014. Please direct inquiries to enzymes@dyadic.com.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic’s website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at (www.otcmarkets.com/stock/DYAI/quote).